Nitric oxide has been determined to be a potential mediator of the haemodynamic changes associated with sepsis. The haemodynamic eects of nitric oxide can be partially antagonised by methylene blue, through inhibition of the enzyme, guanylate cyclase. The case report presented here demonstrates a beneficial haemodynamic eect of continuous infusion of methylene blue during sepsis. These findings could be extrapolated to other patients or prompt additional research.
Nitric oxide has recently been implicated as a potential mediator of both the peripheral vascular and the cardiac reponse to endotoxin which results in the syndrome of septic shock.' Nitric oxide produces these effects by stimulating the soluble guanylate cyclase of vascular smooth muscle and cardiac cells, increasing cyclic GMP levels and producing vascular relaxation and impaired cardiac contraction.' Pharmacologic antagonism of nitric oxide production or receptor interaction has been shown to have beneficial effects on both the peripheral vascular and cardiac response to endotoxin.' Methylene blue has been demonstrated to inhibit guanylate cyclase' and anecdotal experience with methylene blue administration to patients with septic shock refractory to catecholamines has demonstrated short-term benefits of the drug. ' 
Case report
The patient was a previously well, nonimmunocompromised, 61-year-old man who presented to a community hospital with a 10-day history of left-sided chest pain causing shortness of breath. Chest X-ray on the day of presentation demonstrated a left lower lobe consolidation and a left pleural effusion. The provisional diagnosis was community-acquired pneumonia, and cefuroxime and erythromcyin were initiated. The hypoxaemia worsened, necessitating intubation and mechanical ventilation on the following day. Sputum and blood samples grew no pathogens, and a ventilationperfusion scan indicated no pulmonary embolism. To attempt to improve ventilation, a chest tube was placed which evacuated approximately 2.5 litres of a greenish-brown odourless liquid, which subsequently grew Candida albicans and an unidentified yeast. The patient was transferred to this institution after nine days of mechanical ventilation.
On presentation here, the patient was febrile, had a white cell count of 15.5 x 109/l and chest X-ray demonstrated left lower lobe consolidation. A sample of pleural fluid was obtained the next day which grew Candida parapsilosis. A fiberoptic bronchoscopy performed on day 3 was unremarkable and protected brush specimens from the bronchoscopy grew Candida. Despite anti-fungal therapy, the patient deteriorated and developed adult respiratory distress syndrome. On day 33, the patient developed septic haemodynamics requring vasopressors. Sputum and blood samples grew no pathogens; urine culture yielded Enterococcusfaecium and vancomycin was begun. Over a 24 hour period, increasing vasopressor requirements resulted in treatment with dopamine at 10 4ug/kg/min and norepinephrine at 15 Following recovery from the septic episode, the patient's adult respiratory distress sydrome, debilitation and weakness necessitated a slow wean from the ventilator. On day 87 of hospitalisation, the patient was transferred from the intensive care unit to the general medical ward, breathing room air via a tracheostomy.
Discussion
The beneficial haemodynamic effects of methylene blue on septic shock have until now only been demonstrated to be transient.T he patient outcome of those individuals treated in the initial reports was frequently death, despite the apparent short-term haemodynamic benefits of the methylene blue. The mechanism for the attenuation of response to the intermittent administration of methylene blue is unknown, but a variety of pharmacodynamic and pharmacokinetic mechanisms are plausible. Decreased sensitivity of guanylate cyclase to methylene blue over time, or nonguanylate-cyclase-mediated haemodynamic effects are potential mechanisms. Similarly, metabolism, distribution through tissue binding, or excretion of methylene blue may explain the attenuated response. Continuous administration of methylene blue could potentially overcome the pharmacokinetic mechanisms accounting for the attenuation of 7 Methylene blue has been reported to produce a blue -grey skin colouration which may be confused with cyanosis.8
The antagonism of nitric oxide-mediated peripheral vasodilation may counter the beneficial effects of nitrates on myocardial blood flow, resulting in cardiac ischaemia.9 Similarly, methylene blue may inhibit beneficial effects of nitroglycerin on platelet disposition on exposed aortic media. 0 Methylene blue may inhibit platelet aggregation, which could affect haemostasis in thrombotic or haemorrhagic states."l Methylene blue has also been demonstrated to antagonise the anticoagulant effects of heparin."2 The potential for methylene blue to cause haemolytic anaemia should be appreciated. The administration of larger doses (500 mg over 10 minutes) has caused restlessness, anxiety and reversible paresthesias.
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The larger doses also produced dyspepsia and a sensation of burning in the mouth which persisted for 24 hours.'3 Despite methylene blue's potential to cause diverse anti-inflammatory and physiologic effects,'4"15 we were unable to detect any significant toxicity in our patient.
Based on the short-term haemodynamic benefits of methylene blue in septic shock, we would encourage investigators to consider more prolonged administration of the drug. Data on benefit and absence of toxicity can only be obtained through increased investigation.
